What is HC Wainwright’s Forecast for AnaptysBio Q2 Earnings?

AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Analysts at HC Wainwright issued their Q2 2027 earnings per share (EPS) estimates for AnaptysBio in a research note issued on Friday, November 13th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings of $0.38 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $95.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($1.30) per share.

A number of other brokerages have also recently commented on ANAB. Leerink Partners lowered their price target on AnaptysBio from $90.00 to $81.00 and set an “outperform” rating for the company in a research note on Wednesday, September 23rd. Wolfe Research reissued an “outperform” rating and set a $78.00 price objective on shares of AnaptysBio in a research note on Monday, August 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of AnaptysBio in a research report on Tuesday, September 22nd. Wall Street Zen cut AnaptysBio from a “buy” rating to a “hold” rating in a report on Sunday, October 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of AnaptysBio in a report on Wednesday, November 4th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and an average price target of $75.67.

View Our Latest Stock Report on AnaptysBio

AnaptysBio Trading Down 1.1%

Shares of ANAB opened at $45.73 on Tuesday. The stock has a market cap of $1.37 billion, a P/E ratio of 9.22 and a beta of 0.70. AnaptysBio has a 1 year low of $22.01 and a 1 year high of $72.36. The stock’s 50-day moving average price is $49.57 and its two-hundred day moving average price is $56.29.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last released its earnings results on Thursday, November 12th. The biotechnology company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($1.84) by $1.95. AnaptysBio had a negative return on equity of 14.28% and a net margin of 96.30%. The firm had revenue of $30.27 million for the quarter, compared to analyst estimates of $25.56 million.

Insiders Place Their Bets

In other AnaptysBio news, Director Hollings Renton sold 5,000 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $49.87, for a total transaction of $249,350.00. Following the completion of the transaction, the director owned 10,995 shares in the company, valued at approximately $548,320.65. This represents a 31.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 31.50% of the company’s stock.

Institutional Trading of AnaptysBio

Several hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its position in shares of AnaptysBio by 45.6% during the third quarter. Goldman Sachs Group Inc. now owns 850,343 shares of the biotechnology company’s stock worth $42,738,000 after buying an additional 266,273 shares during the period. Entropy Technologies LP bought a new position in shares of AnaptysBio during the third quarter worth about $468,000. HighVista Strategies LLC bought a new position in shares of AnaptysBio during the third quarter worth about $598,000. Voya Investment Management LLC raised its position in AnaptysBio by 55.2% in the 3rd quarter. Voya Investment Management LLC now owns 17,488 shares of the biotechnology company’s stock valued at $879,000 after buying an additional 6,223 shares during the last quarter. Finally, Edgestream Partners L.P. acquired a new stake in AnaptysBio in the 3rd quarter valued at approximately $474,000.

About AnaptysBio

(Get Free Report)

AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.

Read More

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.